An observational study in Novel Influenza A (H1N1) and A New Flu Virus of Swine Origin, sponsored by Novartis Vaccines. Completed at 10 sites in 4 countries. Open to participants aged 6 Months and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-14.
Sponsored by Novartis Vaccines · Observational
This is an observational study of safety and occurrence of influenza-like illness following administration of flu cell culture derived adjuvanted swine origin A (H1N1) pandemic subunit vaccine in subjects 6 months of age and older.
2,214 studies on the registry are indexed under Influenza, Human; 163 are open to participants now.
This study's enrollment of 4,028 is above the median of 300 across 305 observational studies indexed under Influenza, Human.
Browse Influenza, Human studies →Novartis Vaccines is the lead sponsor of 161 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
population of children, adolescents, adults and elderly
Exclusion Criteria:
Other: Non-intervention observational study
Other: Non-intervention observational study
Other: Non-intervention observational study
Other: Non-intervention observational study
Other: Non-intervention observational study
Other: Non-intervention observational study
Non-intervention observational study
To quantify the safety of Flu Cell Culture Derived Adjuvanted Swine Origin A(H1N1) Pandemic Subunit Vaccine in actively monitored subjects
Time frame: 6 months
To characterize the incidence of AEs in specific age groups following an active surveillance of vaccinated subjects
Time frame: 6 months
To assess the occurrence of laboratory confirmed H1N1sw and influenza-like illness following vaccination
Time frame: 6 Months
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis Vaccines